Stockhead
 
Biocurious: In its quest for the “perfect” kidney drug candidate, Dimerix won’t let the grass grow under its feet 

Biocurious: In its quest for the “perfect” kidney drug candidate, Dimerix won’t let the grass grow under its feet 

Having run the ruler over 140 acquisition proposals, Dimerix has settled on a drug program targeting heart surgery related kidney disease.

 
Rise and Shine: Everything you need to know before the ASX opens

Rise and Shine: Everything you need to know before the ASX opens

Here’s everything you need to know before the ASX flings open its doors and begins trading today.

 
 
Twiggy’s $190m ASX tungsten bet sparks fresh focus on Western supply security

Twiggy’s $190m ASX tungsten bet sparks fresh focus on Western supply security

Andrew Forrest’s $190m investment in EQ Resources has thrust tungsten into the spotlight, highlighting Australia’s potential role in providing non-Chinese supply.

 
The race to decarbonise the world’s cities with smart technology

The race to decarbonise the world’s cities with smart technology

Hidden in plain sight, Aussie tech is decarbonising the world’s cities with sustainable wizardry in buildings, highways and ports.

 
Could this rare earths project power AUKUS’ submarines?

Could this rare earths project power AUKUS’ submarines?

Heavy Rare Earths’ Subron project elevated as potential AUKUS supply source after strategic review points to “remarkable” prospectivity.

 
Entropy granted South African patent for psilocybin-based fibromyalgia treatment